PHIO (RXi Pharmaceuticals) Company Projected Revenue

Corporate company logo of Phio Pharmaceuticals Corp. (PHIO)

The key driver for Phio Pharmaceuticals (PHIO) is the INTASYL platform for creating self-delivering RNA interference in immuno-oncology. The company's expected sales volume on the GURU.Markets daily chart reflects the dynamics of this potential, where 0.00 captures the magnitude of this parameter. Preclinical in vivo tests to mitigate risks and the prospects of strategic alliances with the largest pharma behemoths in the untapped niche of precision therapy further strengthen the fundamentals.

PHIO - Phio Pharmaceuticals Projected Sales Volume over the range 07/04/2022 - 11/16/2026

Summary analytical data breakdowns for Phio Pharmaceuticals Corp. (PHIO)

- stock value and consensus price forecast:
Comprehensive company analysis:Phio Pharmaceuticals Corp. PHIO
Brand item of phiopharma.com

Investors assess an asset's operational resilience through the ratio of market capitalization to expected revenue. For Phio Pharmaceuticals (PHIO), the automation of oligonucleotide synthesis via robotics increases drug development precision, impacting future earnings. By analyzing the company's projected sales volume, you can see the dependence of the current share price on expected cash flows. This metric measures market expectations regarding the commercialization of technologies. The indicator's trend confirms the financial viability of the business model.

Key competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|Company Projected Revenue metagenomi.co|Projected Sales Volume Precision BioSciences Inc.|Projected Sales Volume GBIO|Boundless Bio, Inc. - Company Revenue Forecast|Projected Sales Volume XCUR (Exicure, Inc.)|Company Future Sales Imunon, Inc. (IMNN)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume